| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Mar'13 | Mar'12 | Mar'11 | Mar'10 |
|---|---|---|---|---|---|---|---|---|---|
REVENUES: | |||||||||
Other | |||||||||
- | - | - | - | - | - | - | - | - | 5,002 |
Total revenues | |||||||||
1,170,947 | 1,094,274 | 903,374 | 745,694 | 628,335 | 618,789 | 575,548 | 389,977 | 186,640 | 178,281 |
EXPENSES: | |||||||||
Cost of goods manufactured and sold (exclusive of amortization of acquired intangible assets shown below) | |||||||||
180,385 | 176,420 | 154,748 | 132,122 | 138,989 | 175,832 | 170,466 | 127,578 | 52,185 | 49,438 |
Research and development | |||||||||
512,833 | 425,406 | 412,889 | 387,148 | 344,404 | 272,043 | 140,013 | 141,893 | 97,239 | 95,363 |
Selling, general and administrative | |||||||||
599,449 | 526,408 | 421,578 | 374,130 | 311,558 | 199,905 | 125,758 | 137,632 | 82,847 | 76,514 |
Amortization of acquired intangible assets | |||||||||
40,400 | 65,200 | 62,100 | 60,959 | 57,685 | 58,153 | 41,852 | 25,355 | - | - |
Restructuring expense | |||||||||
13,401 | - | - | - | - | - | 12,300 | - | - | - |
Impairment of long-lived assets | |||||||||
- | - | - | - | - | - | 3,346 | 45,800 | - | - |
Total expenses | |||||||||
1,346,426 | 1,193,402 | 1,051,274 | 954,359 | 852,636 | 705,933 | 493,735 | 478,258 | 232,271 | 221,315 |
OPERATING LOSS | |||||||||
-175,479 | -99,128 | -147,900 | -208,665 | -224,301 | -87,144 | 81,813 | -88,281 | -45,631 | -43,034 |
OTHER INCOME (EXPENSE), NET: | |||||||||
Interest income | |||||||||
13,976 | 9,238 | 4,649 | 3,752 | 3,330 | 1,972 | 841 | 1,516 | 2,728 | 4,667 |
Interest expense | |||||||||
13,601 | 15,437 | 12,008 | 14,889 | 13,247 | 13,430 | 48,994 | 28,111 | 3,298 | 5,974 |
Change in the fair value of contingent consideration | |||||||||
-22,800 | -19,600 | 21,600 | 7,900 | -2,300 | - | - | - | - | - |
Gain on the Gainesville Transaction | |||||||||
- | - | - | - | 9,636 | - | - | - | - | - |
Gain on sale of property, plant and equipment | |||||||||
- | - | - | - | 2,862 | 41,933 | - | - | - | - |
Gain on sale of investment in Civitas Therapeutics, Inc. | |||||||||
- | - | - | - | - | 29,564 | - | - | - | - |
Gain on sale of investment in Acceleron Pharma Inc. | |||||||||
- | - | - | - | - | 15,296 | - | - | - | - |
Other expense, net | |||||||||
848 | -2,040 | -9,615 | -2,485 | 15 | -2,220 | 1,781 | 484 | -290 | -360 |
Total other income (expense), net | |||||||||
-21,577 | -27,839 | 4,626 | -5,722 | 296 | 73,115 | -46,372 | -26,111 | -860 | -1,667 |
LOSS BEFORE INCOME TAXES | |||||||||
-197,056 | -126,967 | -143,274 | -214,387 | -224,005 | -14,029 | 35,441 | -114,392 | -46,491 | -44,701 |
INCOME TAX PROVISION (BENEFIT) | |||||||||
-436 | 12,344 | 14,671 | -5,943 | 3,158 | 16,032 | 10,458 | -714 | -951 | -5,075 |
NET LOSS | |||||||||
-196,620 | -139,311 | -157,945 | -208,444 | -227,163 | -30,061 | 24,983 | -113,678 | -45,540 | -39,626 |
LOSS PER ORDINARY SHARE: | |||||||||
Basic and diluted (in dollars loss per ordinary share) | |||||||||
-1.25 | -0.90 | -1.03 | -1.38 | -1.52 | -0.21 | - | - | - | - |
Basic (in dollars per share) | |||||||||
- | - | - | - | - | - | 0.19 | -0.99 | -0.48 | -0.42 |
Diluted (in dollars per share) | |||||||||
- | - | - | - | - | - | 0.18 | -0.99 | -0.48 | -0.42 |
WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING: | |||||||||
Basic and diluted (in shares) | |||||||||
157,051 | 155,112 | 153,415 | 151,484 | 149,206 | 145,274 | - | - | - | - |
Basic (in shares) | |||||||||
- | - | - | - | - | - | 131,713 | 114,702 | 95,610 | 94,839 |
Diluted (in shares) | |||||||||
- | - | - | - | - | - | 137,100 | 114,702 | 95,610 | 94,839 |
COMPREHENSIVE LOSS: | |||||||||
Net loss | |||||||||
-196,620 | -139,311 | -157,945 | -208,444 | -227,163 | -30,061 | 24,983 | -113,678 | -45,540 | -39,626 |
Unrealized gain, net of a tax provision of $87 and $229, respectively | |||||||||
1,464 | 512 | -518 | 522 | -661 | 1,586 | 703 | 627 | 379 | 2,998 |
Unrealized losses on derivative contracts, net of tax of none, none and $(194), respectively | |||||||||
- | - | - | - | - | - | -72 | -327 | - | - |
Less: Reclassification adjustment for gains included in net (loss) income | |||||||||
- | - | - | - | - | 15,296 | -594 | - | - | - |
Less: Reclassification adjustment for gains included in net (loss) income | |||||||||
- | - | - | - | - | - | -1,030 | - | - | - |
Unrealized gains (losses) on marketable securities | |||||||||
- | - | - | - | - | - | -327 | 627 | 379 | 3,092 |
Unrealized gains on derivative contracts | |||||||||
- | - | - | - | - | - | 522 | -327 | - | - |
COMPREHENSIVE LOSS | |||||||||
-195,156 | -138,799 | -158,463 | -207,922 | -227,824 | -43,771 | 25,178 | -113,378 | -45,161 | -36,534 |
Product sales, net | |||||||||
Total revenues | |||||||||
524,499 | 450,334 | 362,834 | 256,146 | 149,028 | 94,160 | 58,107 | 41,184 | 28,920 | 20,245 |
Manufacturing and royalty revenues | |||||||||
Total revenues | |||||||||
447,882 | 526,675 | 505,308 | 487,247 | 475,288 | 516,876 | 510,900 | 326,444 | 156,840 | 149,917 |
Research and development revenue | |||||||||
Total revenues | |||||||||
52,816 | 68,895 | 7,232 | 2,301 | 4,019 | 7,753 | 6,541 | 22,349 | 880 | 3,117 |
License revenue | |||||||||
Total revenues | |||||||||
145,750 | 48,370 | 28,000 | - | - | - | - | - | - | - |